Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Enfermedades Renales , Enfermedades Cardiovasculares , España , Estudios Retrospectivos , Estudios de Casos y Controles , Servicio de Urgencia en HospitalRESUMEN
This work presents a tool for forecasting the spread of the new coronavirus in Mexico City, which is based on a mathematical model with a metapopulation structure that uses Bayesian statistics and is inspired by a data-driven approach. The daily mobility of people in Mexico City is mathematically represented by an origin-destination matrix using the open mobility data from Google and the Transportation Mexican Survey. This matrix is incorporated in a compartmental model. We calibrate the model against borough-level incidence data collected between 27 February 2020 and 27 October 2020, while using Bayesian inference to estimate critical epidemiological characteristics associated with the coronavirus spread. Given that working with metapopulation models leads to rather high computational time consumption, and parameter estimation of these models may lead to high memory RAM consumption, we do a clustering analysis that is based on mobility trends to work on these clusters of borough separately instead of taken all of the boroughs together at once. This clustering analysis can be implemented in smaller or larger scales in different parts of the world. In addition, this clustering analysis is divided into the phases that the government of Mexico City has set up to restrict individual movement in the city. We also calculate the reproductive number in Mexico City using the next generation operator method and the inferred model parameters obtaining that this threshold is in the interval (1.2713, 1.3054). Our analysis of mobility trends can be helpful when making public health decisions.
Asunto(s)
COVID-19/epidemiología , Transportes , Número Básico de Reproducción , Análisis por Conglomerados , Geografía , Humanos , México/epidemiología , Modelos Biológicos , Probabilidad , Reproducibilidad de los ResultadosRESUMEN
Objetivos: Identificar las comorbilidades prioritarias en la espondiloartritis axial (EspAx) y recomendar cómo hacer su seguimiento desde una perspectiva eminentemente práctica. Métodos: Se seleccionó a un grupo multidisciplinar (10 reumatólogos [6 expertos en EspAx], 2 médicos de familia, una internista, una cardióloga, una gastroenteróloga y una psicóloga). En una primera reunión de discusión, se establecieron el alcance y los usuarios, y se votó una lista de comorbilidades sobre la base de la frecuencia y el impacto. Los panelistas debían defender con argumentos consistentes la inclusión de cada comorbilidad/ítem en el documento. Cuatro panelistas y 2 metodólogos, desarrollaron revisiones sistemáticas en temas controvertidos. En una segunda reunión se presentaron los resultados de las revisiones y los argumentos de todos los ítems a incluir. Tras esta reunión se redactó el documento final. Resultados: El documento final incluye 2 listas de comprobación (checklist), una para profesionales sanitarios y otra para pacientes, que recogen: riesgo cardiovascular, comorbilidad renal, riesgo gastrointestinal, estilo de vida, riesgo de infecciones y vacunación, afectación pulmonar, medicación concomitante, trastornos psicoafectivos, osteoporosis y riesgo de fractura. Además, el documento refleja los argumentos para incluir cada ítem y la manera de recoger los ítems. Asimismo, el panel consideró oportuno establecer unas «prácticas a evitar» aplicables a la comorbilidad de la EspAx. Conclusiones: Se generaron 2 listas de comprobación y un listado de escenarios a evitar para facilitar el manejo de las comorbilidades de la EspAx. En pasos posteriores probaremos su utilidad y su aceptación por un grupo amplio de usuarios que incluya médicos, pacientes y enfermeras
Objectives: To identify priorities among comorbidities in axial spondyloarthritis (AxSpA) and recommend how to follow them from an eminently practical perspective. Methods: A multidisciplinary group was selected (10 rheumatologists-six of them experts in AxSpA-, 2 general practitioners, an internist, a cardiologist, a gastroenterologist and a psychologist). In a first discussion meeting, the scope and users were established and a list of comorbidities was voted based on frequency and impact. The panelists had to defend the inclusion of each comorbidity/item in the document with consistent arguments. Four panelists and two methodologists developed systematic reviews on controversial topics. In a second meeting, the results of the reviews and the arguments concerning the items to be included were presented. After the meeting, the final document was drafted. Results: The final document includes two checklists, one for health professionals and another for patients; they incorporate cardiovascular risk, renal comorbidities, gastrointestinal risk, lifestyle, risk of infections and vaccinations, pulmonary involvement, concomitant medication, psycho-affective disorders, osteoporosis, and risk of fracture. In addition, the document reflects the arguments favoring the inclusion of each item and how to record the items for subsequent collection. The panel considered it also appropriate to likewise establish «practices to avoid» applicable to comorbidity in AxSpA. Conclusions: Two checklists and a list of situations to avoid were generated to facilitate the management of comorbidities in AxSpA. In a future step, their utility and acceptance will be tested by a broad group of users that includes doctors, patients and nurses
Asunto(s)
Humanos , Espondiloartritis/complicaciones , Osteoporosis/epidemiología , Enfermedades Cardiovasculares/epidemiología , Enfermedades Renales/epidemiología , Enfermedades Gastrointestinales/epidemiología , Factores de Riesgo , Comorbilidad , Grupo de Atención al Paciente/organización & administración , Fracturas Osteoporóticas/epidemiología , Pautas de la Práctica en MedicinaRESUMEN
OBJECTIVES: To identify priorities among comorbidities in axial spondyloarthritis (AxSpA) and recommend how to follow them from an eminently practical perspective. METHODS: A multidisciplinary group was selected (10 rheumatologists-six of them experts in AxSpA-, 2 general practitioners, an internist, a cardiologist, a gastroenterologist and a psychologist). In a first discussion meeting, the scope and users were established and a list of comorbidities was voted based on frequency and impact. The panelists had to defend the inclusion of each comorbidity/item in the document with consistent arguments. Four panelists and two methodologists developed systematic reviews on controversial topics. In a second meeting, the results of the reviews and the arguments concerning the items to be included were presented. After the meeting, the final document was drafted. RESULTS: The final document includes two checklists, one for health professionals and another for patients; they incorporate cardiovascular risk, renal comorbidities, gastrointestinal risk, lifestyle, risk of infections and vaccinations, pulmonary involvement, concomitant medication, psycho-affective disorders, osteoporosis, and risk of fracture. In addition, the document reflects the arguments favoring the inclusion of each item and how to record the items for subsequent collection. The panel considered it also appropriate to likewise establish «practices to avoid¼ applicable to comorbidity in AxSpA. CONCLUSIONS: Two checklists and a list of situations to avoid were generated to facilitate the management of comorbidities in AxSpA. In a future step, their utility and acceptance will be tested by a broad group of users that includes doctors, patients and nurses.
Asunto(s)
Espondiloartritis/epidemiología , Lista de Verificación , Comorbilidad , Humanos , España/epidemiología , Espondiloartritis/terapiaRESUMEN
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/complicaciones , Artritis Reumatoide/tratamiento farmacológico , Linfoma/epidemiología , Linfoma/etiología , Europa (Continente)/epidemiología , Femenino , Humanos , Linfoma/patología , Linfoma de Células B/epidemiología , Linfoma de Células B/etiología , Linfoma no Hodgkin/epidemiología , Linfoma no Hodgkin/etiología , Linfoma de Células T/epidemiología , Linfoma de Células T/etiología , Masculino , Persona de Mediana Edad , Sistema de Registros , Factores de Riesgo , Inhibidores del Factor de Necrosis TumoralRESUMEN
OBJECTIVE: Several aspects of rituximab (RTX) retreatment in rheumatoid arthritis (RA) need to be further elucidated. The aim of this study was to describe the effect of repeated courses of RTX on disease activity and to compare 2 retreatment strategies, fixed-interval versus on-flare retreatment, in a large international, observational, collaborative study. METHODS: In the first analysis, patients with RA who received at least 4 cycles with RTX were included. In the second analysis, patients who received at least 1 RTX retreatment and for whom information about the strategy for retreatment was available were identified. Two retreatment strategies (fixed-interval vs on-flare) were compared by fitting-adjusted, mixed-effects models of 28-joint Disease Activity Score (DAS28) over time for first and second retreatment. RESULTS: A total of 1530 patients met the eligibility criteria for the first analysis. Significant reductions of mean DAS28 between the starts of subsequent treatment cycles were observed (at start of first treatment cycle: 5.5; second: 4.3; third: 3.8; and fourth: 3.5), suggesting improved response after each additional cycle (p < 0.0001 for all pairwise comparisons). A total of 800 patients qualified for the second analysis: 616 were retreated on flare and 184 at fixed interval. For the first retreatment, the fixed-interval retreatment group yielded significantly better results than the on-flare group (estimated marginal mean DAS28 = 3.8, 95% CI 3.6-4.1 vs 4.6, 95% CI 4.5-4.7, p < 0.0001). Similar results were found for the second retreatment. CONCLUSION: Repeated treatment with RTX leads to further clinical improvement after the first course of RTX. A fixed-interval retreatment strategy seems to be more effective than on-flare retreatment.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Rituximab/uso terapéutico , Adulto , Anciano , Artritis Reumatoide/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sistema de Registros , Retratamiento , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
OBJECTIVES: To analyse clinical, serological and sonographic differences between rheumatoid arthritis (RA) and polyarticular psoriatic arthritis (PsA) patients on anti-TNF therapy in clinical remission. METHODS: Angiogenic and proinflammatory cytokine serum levels were determined by multiplex ELISA in patients with RA and PsA in clinical remission (DAS28-ESR<2.6), clinically-active RA patients (DAS28>3.2) and healthy controls. Ultrasound (US) scans were made of both wrists and hands. RESULTS: 30 RA and 47 PsA patients in remission, 22 active RA patients and 20 healthy controls were included. PsA patients had significantly lower disease activity according to DAS28-ESR (p=0.006) but not according to DAS28-CRP (p=0.319), and lower serum levels of proinflammatory and angiogenic cytokines than RA patients in remission. PsA patients had cytokine levels similar to healthy controls, while RA patients in remission had similar levels to those of active RA patients. Globally, 31 (40.25%) patients in remission had a PD signal and 12 had SH>2 plus PD [1 PsA vs. 11 RA (p=0.0001)], meeting the criteria for ultrasound-defined active synovitis (UdAS). Patients with UdAS had significantly higher levels of IL-6, IL-20, PIGF and SDF1. More PsA patients were on tapered doses of anti-TNF (63.8%), and more frequently as monotherapy (72.3%), compared with RA patients (26.6% and 20%, respectively). CONCLUSIONS: Polyarticular PsA patients in remission had lower levels of local (US synovitis) and systemic inflammation than RA patients in remission, even though a significantly higher percentage of PsA patients were on tapered doses of anti-TNF, mainly in monotherapy.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Citocinas/sangre , Inflamación/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Anciano , Artritis Psoriásica/sangre , Artritis Psoriásica/diagnóstico por imagen , Artritis Psoriásica/patología , Artritis Reumatoide/sangre , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/patología , Progresión de la Enfermedad , Femenino , Articulaciones de la Mano/diagnóstico por imagen , Humanos , Inflamación/sangre , Inflamación/diagnóstico por imagen , Inflamación/patología , Masculino , Persona de Mediana Edad , Inducción de Remisión , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Ultrasonografía , Articulación de la Muñeca/diagnóstico por imagenRESUMEN
BACKGROUND: Digoxin is a frequently prescribed drug in the elderly population. Estimated glomerular filtration rate is widely used to adjust dosages. The HUGE value is a tool for differentiating the presence or absence of chronic kidney disease in elderly patients. We aimed to investigate the usefulness of the HUGE value to predict the initial dose of digoxin in patients aged older than 70 years. METHODS: We reviewed retrospectively the medical records of patients aged older than 70 years with serum digoxin concentrations (SDCs) monitored over a 6-month period (63 patients). A linear regression relating the patient's SDC, maintenance dose of digoxin and the HUGE value was estimated to generate a dosage equation. This equation was validated retrospectively (33 patients) and prospectively (35 patients) in comparison with two existing methods based on creatinine clearance. RESULTS: An equation (HUGE_DIG) was generated to calculate the initial digoxin dose to reach a specific target SDC. Thus, to achieve a SDC of 0.8 ng/mL: Digoxin (mg/day) = 0.091 - 0.006 x HUGE. After retrospective validation, the calculated digoxin doses with this equation were administered in the prospective phase and we did not observe statistical differences between measured and desired SDCs. Moreover, the predictive performance of our equation was better than that obtained with the compared methods. CONCLUSIONS: We offer a new validated digoxin dosing equation for elderly patients. Our results support the need to perform digoxin dosing in elderly people, bearing in mind the changes in renal physiology secondary to ageing and not merely the estimated glomerular filtration rate.
Asunto(s)
Envejecimiento , Digoxina/administración & dosificación , Anciano , Anciano de 80 o más Años , Algoritmos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Pruebas de Función Renal , Masculino , Estudios RetrospectivosRESUMEN
OBJECTIVES: To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-modifying antirheumatic drugs (sDMARDs) in a large observational study. METHODS: Patients with rheumatoid arthritis treated with TCZ who had a baseline visit and information on concomitant sDMARDs were included. According to baseline data, patients were considered as taking TCZ as monotherapy or combination with sDMARDs. Main study outcomes were the change of Clinical Disease Activity Index (CDAI) and TCZ retention. The prescription of TCZ as monotherapy was analysed using logistic regression. CDAI change was analysed with a mixed-effects model for longitudinal data. TCZ retention was analysed with a stratified extended Cox model. RESULTS: Multiple-adjusted analysis suggests that prescription of TCZ as monotherapy varied according to age, corticosteroid use, country of the registry and year of treatment initiation. The change of disease activity assessed by CDAI as well as the likelihood to be in remission were not significantly different whether TCZ was used as monotherapy or in combination with sDMARDs in a covariate-adjusted analysis. Estimates for unadjusted median TCZ retention were 2.3â years (95% CI 1.8 to 2.7) for monotherapy and 3.7â years (lower 95% CI limit 3.1, upper limit not estimable) for combination therapies. In a covariate-adjusted analysis, TCZ retention was also reduced when used as monotherapy, with an increasing difference between mono and combination therapy over time after 1.5â years (p=0.002). CONCLUSIONS: TCZ with or without concomitant sDMARDs resulted in comparable clinical response as assessed by CDAI change, but TCZ retention was shorter under monotherapy of TCZ.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Quimioterapia Combinada , Europa (Continente) , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
OBJECTIVE: To investigate the presence of subclinical synovitis by ultrasound (US) and the clinical phenotype in patients with palindromic rheumatism (PR) according to anticitrullinated protein antibody (ACPA) status. METHODS: Fifty-four patients with PR were studied. Clinical, demographic, serological, and therapeutic characteristics were compared in ACPA-positive and ACPA-negative patients. US searching for synovial hypertrophy (SH) and power Doppler signal (PDUS) in 22 joints of the hands was performed in the intercritical period. The results were compared according to ACPA status and with a healthy control group (n = 30). In 10 patients, US was performed during the joint attack. RESULTS: Most patients were female (63%) with a mean disease duration of 11.6 ± 10.7 years. Thirty-six patients (66.7%) were ACPA-positive. ACPA-positive patients had a shorter duration of attacks, a younger age, and less knee involvement at disease onset. US examination showed SH grade ≥ 1 in 79.6% of patients with PR and 50% of controls. Significant US results (SH ≥ 2 or PDUS) were observed in 2.7% and 1.4% of joints assessed and in 33% and 25.9% of patients with PR, respectively. Only 4 patients (7.4%) had US active synovitis (SH ≥ 2 plus PDUS) in at least 1 joint. US assessment showed no significant differences between ACPA-positive and ACPA-negative patients. PDUS was observed in 7 out of 10 patients during attacks. CONCLUSION: Some differences emerged in the clinical phenotype of PR according to ACPA status. Most patients with PR do not have US subclinical synovitis in the intercritical period, even those who are ACPA-positive.
Asunto(s)
Anticuerpos Antiidiotipos/sangre , Artritis Reumatoide/complicaciones , Péptidos Cíclicos/inmunología , Sinovitis/diagnóstico por imagen , Sinovitis/diagnóstico , Adulto , Anciano , Anticuerpos Antiidiotipos/inmunología , Estudios de Casos y Controles , Progresión de la Enfermedad , Femenino , Humanos , Hipertrofia , Masculino , Persona de Mediana Edad , Fenotipo , Índice de Severidad de la Enfermedad , Membrana Sinovial/diagnóstico por imagen , Membrana Sinovial/patología , Sinovitis/inmunología , UltrasonografíaRESUMEN
OBJECTIVE: Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and in small series of patients with AOSD. The aim of this multicenter study was to assess the efficacy of TCZ in patients with AOSD refractory to conventional treatment. METHODS: This was a retrospective open-label study of TCZ treatment in 34 patients with AOSD who had experienced an inadequate response to corticosteroids and at least 1 standard synthetic immunosuppressive drug and also, in many cases, biologic agents. RESULTS: The mean ± SD age of the patients (8 men and 26 women) was 38.7 ± 16.1 years. The median duration of AOSD before TCZ was initiated was 4.2 years (interquartile range [IQR] 1-9 years). The initial dosages of intravenous TCZ were 8 mg/kg every 4 weeks in 22 patients, 4 mg/kg every 4 weeks in 2 patients, and 8 mg/kg every 2 weeks in 10 patients. TCZ treatment resulted in rapid and maintained improvement in both clinical and laboratory parameters. After 1 year of TCZ therapy, the incidence of joint manifestations had decreased from 97.1% at baseline to 32.4%, the incidence of both cutaneous manifestations and fever had decreased from 58.8% to 5.9%, and the incidence of lymphadenopathy had decreased from 29.4% to 0%. A dramatic reduction in laboratory markers of inflammation, including the C-reactive protein level, the erythrocyte sedimentation rate, and the ferritin level, was achieved. The median dosage of prednisone was also reduced, from 13.8 mg/day (IQR 5-45) at the initiation of TCZ to 2.5 mg/day (IQR 0-30) at 12 months. After a median followup of 19 months (IQR 12-31 months), only 2 patients required permanent discontinuation of TCZ therapy because of severe infections. CONCLUSION: TCZ treatment was associated with rapid and maintained clinical and laboratory improvement in patients with AOSD refractory to standard treatment. However, joint manifestations seem to be more refractory to treatment compared with systemic manifestations.
Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Still del Adulto/tratamiento farmacológico , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anticuerpos Monoclonales/inmunología , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Receptores de Interleucina-6/inmunología , Estudios Retrospectivos , Insuficiencia del Tratamiento , Resultado del Tratamiento , Adulto JovenRESUMEN
Objetivo. Analizar la frecuencia y características de la reducción de dosis de fármacos biológicos en una cohorte de pacientes con artritis crónica, en condiciones de práctica clínica de un hospital de tercer nivel. Material y métodos. Estudio descriptivo y transversal, que incluyó a todos los pacientes visitados consecutivamente durante 6 meses(junio de 2011-noviembre de 2011) por un solo investigador, con pacientes que habían recibido al menos una dosis de fármaco biológico durante el año 2011. Resultados. Se incluyeron 153 pacientes: artritis reumatoide (AR) (n = 82), espondilitis anquilosante (n = 29), artritis psoriásica (n = 20)y grupo miscelánea (n = 22) con una evolución media de 14,9 ± 7,7 años. En el momento del análisis, 70 pacientes (45,7%) estaba con dosis reducida (un 50% en el grupo miscelánea; un 50% en artritis psoriásica; un 48,2% en espondilitis anquilosante, y un 42,6% en AR). El tiempo medio de reducción de dosis fue de 17,4 ± 17,5 meses. Los fármacos biológicos más utilizados a dosis reducidas fueron: etanercept, adalimumab y tocilizumab; el 57,6, el 54,9 y el 40 respectivamente de los pacientes tratados con estos agentes lo hacían a dosis reducidas. Los pacientes con dosis reducidas en comparación con aquellos con dosis normales tenían un mismo tiempo de evolución de la enfermedad, pero recibían menos FAME, glucocorticoides y AINE, con un tiempo similar de uso del agente biológico. Los pacientes con AR y dosis reducidas tenían, en el momento del análisis, mayores índices de remisión que los pacientes con dosis normales (82,9 vs. 34%, p < 0,0001). La decisión terapéutica en el momento del análisis fue mantener la dosis reducida en la práctica totalidad de los pacientes. Conclusión. En nuestra práctica clínica, el 45,7% de los pacientes con artritis crónica reciben terapia biológica a dosis reducidas, tras haber alcanzado la remisión o baja actividad a dosis estándares, manteniendo la mayoría de ellos un buen control de la enfermedad (AU)
Objective: To analyze the frequency and characteristics of dose reduction of biological agents in a cohort of patients with chronic arthritis, in clinical practice conditions in a tertiary level hospital. Material and methods: Descriptive, cross-sectional study, which included all patients, followed consecutively during 6 months (June 2011-November 2011), by one investigator, with patients who at least have received one dose of biological agents in 2011. Results: We included 153 patients: Rheumatoid arthritis (RA) (n = 82), ankylosing spondylitis (n = 29), psoriatic arthritis (n = 20), and miscellaneous group (n = 22). Mean disease duration was 14.9 ± 7.7 years. At the time of analysis, 70 patients (45.7%) were receiving low doses of biological therapy (50% in miscellaneous group group, 50% in psoriatic arthritis, 48.2% in ankylosing spondylitis, and 42.6% in RA). Mean time of dosage reduction was 17.4 ± 17.5 months. The most common biological agents used in low dose were: etanercept, adalimumab and tocilizumab; 57.6%, 54.9% and 40% respectively, in patients with a reduced dose of biological therapy. The patients at low dose of biological therapy compared with standard dose, had similar mean disease duration, but received significantly less DMARDs, glucocorticoids and NSAIDs, and similar biological agent duration. RA patients with reduced biological treatment, at the time of analysis, had higher remission rates versus patients receiving a standard dose (82.9% vs 34%, p < 0.0001). The medical decision at the time of analysis was to maintain low-dosage biological treatment in almost all patients. Conclusion: In our clinical practice, 45.7% of our chronic arthritis patients receive low dose of biological therapy, after achieving remission or low activity at standard doses, maintaining a good control of the disease (AU)
Asunto(s)
Humanos , Masculino , Femenino , Terapia Biológica/instrumentación , Terapia Biológica/métodos , Terapia Biológica , Enfermedades Reumáticas/terapia , Artropatía Neurógena/terapia , Artritis/terapia , Artritis Reumatoide/terapia , Terapia Biológica/estadística & datos numéricos , Terapia Biológica/tendencias , Estudios de Cohortes , Estudios Transversales/métodos , Estudios Transversales/tendencias , Estudios Transversales , Estudios RetrospectivosRESUMEN
Objetivo. Evaluar la afectación laríngea en pacientes con AR en la práctica diaria y correlacionar los hallazgos con las diferentes manifestaciones de la enfermedad, incluyendo la gravedad de la misma. Métodos. Realizamos un estudio transversal a 36 pacientes consecutivos diagnosticados de AR a los cuales se les realizó una exploración sistemática de su enfermedad, una anamnesis dirigida para síntomas de reflujo y valoración del índice de discapacidad vocal. La exploración laríngea se realizó mediante videolaringoestroboscopia (VLE). Resultados. El tiempo medio de evolución de la enfermedad fue de 2,6 ± 3,4 años. El requerimiento vocal se consideró profesional en 12 pacientes (33,3%). Veinticuatro (67%) pacientes presentaron algún hallazgo patológico en la VLE. Se evidenciaron nódulos en bambú en una paciente (2,8%), signos de disfonía hipertónica en 11 pacientes (30,6%) y en 23 pacientes (63,9%) se evidenciaron síntomas y signos de reflujo faringolaríngeo (RFL). No se observaron alteraciones de la movilidad cricoaritenoidea. Conclusiones. En nuestra cohorte las lesiones laríngeas valoradas por VLE en la AR son poco frecuentes. No obstante, alrededor del 60% de los pacientes presenta síntomas y signos de RFL. Dichos hallazgos no se correlacionaron con las características clínicas, la gravedad o el tratamiento de la enfermedad (AU)
Aim: To evaluate the larynx involvement in patients with rheumatoid arthritis (RA) in a clinical setting and correlate with the different clinical features related to more aggressive disease. Methods: Cross-sectional study including 36 consecutive patients with RA. Reflux symptoms were evaluated by the Reflux Symptom Index (RSI) and vocal cord impairment by the Voice Handicap Index-10 (VHI-10). Laryngeal involvement was done by videolaryngostroboscopy (VLS). Results: The mean age was 56,3 ± 14 years with a mean disease duration of 2,6 ± 3,1 years (range 0- 16 years). Voice use was considered as professional users in 33%. Twenty-four (67%) out of 36 patients had abnormal findings of VLS. One patient had larynx nodules (bamboo nodules). Eleven patients (31%) were diagnosed with muscle tension dysphonia, and there were symptoms and signs of pharyngeal-laryngeal reflux in 23 (64%) patients. No signs of cricoarytenoid joint impairment was found. Conclusions: Organic larynx involvement was uncommon in patients with RA. However symptoms and signs of pharyngeal-laryngeal reflux were seen in around 60% of patients. There was no correlation between the clinical phenotype, severity of disease, immunological profile or treatment with VLS findings (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Artritis Reumatoide/complicaciones , Enfermedades de la Laringe/epidemiología , Disfonía/epidemiología , Laringoscopía/métodos , Disfunción de los Pliegues Vocales/diagnóstico , Índice de Severidad de la Enfermedad , Estroboscopía/métodos , Estudios Transversales , Antirreumáticos/uso terapéutico , Biomarcadores/análisisRESUMEN
AIM: To evaluate the larynx involvement in patients with rheumatoid arthritis (RA) in a clinical setting and correlate with the different clinical features related to more aggressive disease. METHODS: Cross-sectional study including 36 consecutive patients with RA. Reflux symptoms were evaluated by the Reflux Symptom Index (RSI) and vocal cord impairment by the Voice Handicap Index-10 (VHI-10). Laryngeal involvement was done by videolaryngostroboscopy (VLS). RESULTS: The mean age was 56,3 ± 14 years with a mean disease duration of 2,6 ± 3,1 years (range 0-16 years). Voice use was considered as professional users in 33%. Twenty-four (67%) out of 36 patients had abnormal findings of VLS. One patient had larynx nodules (bamboo nodules). Eleven patients (31%) were diagnosed with muscle tension dysphonia, and there were symptoms and signs of pharyngeal-laryngeal reflux in 23 (64%) patients. No signs of cricoarytenoid joint impairment was found. CONCLUSIONS: Organic larynx involvement was uncommon in patients with RA. However symptoms and signs of pharyngeal-laryngeal reflux were seen in around 60% of patients. There was no correlation between the clinical phenotype, severity of disease, immunological profile or treatment with VLS findings.
Asunto(s)
Artritis Reumatoide/complicaciones , Enfermedades de la Laringe/diagnóstico , Laringoscopía , Estroboscopía , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Humanos , Enfermedades de la Laringe/etiología , Laringoscopía/métodos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Grabación en VideoRESUMEN
OBJECTIVE: To analyze the frequency and characteristics of dose reduction of biological agents in a cohort of patients with chronic arthritis, in clinical practice conditions in a tertiary level hospital. MATERIAL AND METHODS: Descriptive, cross-sectional study, which included all patients, followed consecutively during 6 months (June 2011-November 2011), by one investigator, with patients who at least have received one dose of biological agents in 2011. RESULTS: We included 153 patients: Rheumatoid arthritis (RA) (n=82), ankylosing spondylitis (n=29), psoriatic arthritis (n=20), and miscellaneous group (n=22). Mean disease duration was 14.9±7.7 years. At the time of analysis, 70 patients (45.7%) were receiving low doses of biological therapy (50% in miscellaneous group group, 50% in psoriatic arthritis, 48.2% in ankylosing spondylitis, and 42.6% in RA). Mean time of dosage reduction was 17.4±17.5 months. The most common biological agents used in low dose were: etanercept, adalimumab and tocilizumab; 57.6%, 54.9% and 40% respectively, in patients with a reduced dose of biological therapy. The patients at low dose of biological therapy compared with standard dose, had similar mean disease duration, but received significantly less DMARDs, glucocorticoids and NSAIDs, and similar biological agent duration. RA patients with reduced biological treatment, at the time of analysis, had higher remission rates versus patients receiving a standard dose (82.9% vs 34%, p<0.0001). The medical decision at the time of analysis was to maintain low-dosage biological treatment in almost all patients. CONCLUSION: In our clinical practice, 45.7% of our chronic arthritis patients receive low dose of biological therapy, after achieving remission or low activity at standard doses, maintaining a good control of the disease.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Antirreumáticos/administración & dosificación , Artritis/tratamiento farmacológico , Inmunoglobulina G/administración & dosificación , Inmunosupresores/administración & dosificación , Receptores del Factor de Necrosis Tumoral/administración & dosificación , Adalimumab , Adulto , Anciano , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Enfermedad Crónica , Estudios Transversales , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Etanercept , Femenino , Humanos , Inmunoglobulina G/uso terapéutico , Inmunosupresores/uso terapéutico , Infliximab , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Estudios Retrospectivos , Espondilitis Anquilosante/tratamiento farmacológico , Resultado del TratamientoRESUMEN
OBJECTIVE: To analyze the incidence rate (IR) and risk factors of cutaneous adverse events (CAE) in patients with chronic inflammatory rheumatic diseases treated with tumor necrosis factor (TNF) antagonists. METHODS: We analyzed all patients from the BIOBADASER (Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología) registry treated with a TNF antagonist (infliximab, etanercept, or adalimumab). Data collected included age, sex, diagnosis and duration of rheumatic disease, type of TNF antagonist, and concomitant treatment. Type of CAE was classified as local or systemic cutaneous manifestation related to treatment administration (infusion reaction), infection, malignancy, or autoimmune skin disease. Time of onset of CAE and outcome were also recorded. The IRs of CAE per 1,000 patient-years of exposure with 95% confidence intervals (95% CIs) were estimated. Multivariable analysis was performed to identify potential risk factors for CAE. RESULTS: A total of 5,437 patients were included, representing 17,330 patient-years of exposure. A total of 920 CAE were reported; the IRs per 1,000 patient-years were 53 (95% CI 50-57) for CAE, 28 (95% CI 25-30) for infection, 15 (95% CI 13-17) for infusion reactions, 5 (95% CI 4-6) for autoimmune skin diseases, and 3 (95% CI 2-4) for skin malignancy. The mean time between starting TNF antagonist treatment and CAE was 1.78 years. In 32% of patients, CAE required TNF antagonist withdrawal. The main risk factors for CAE were female sex and treatment with infliximab, leflunomide, and glucocorticoids. CONCLUSION: The IR of CAE in patients treated with TNF antagonists is significant and should be addressed carefully, and withdrawal of therapy is required in some cases.
Asunto(s)
Antirreumáticos/efectos adversos , Enfermedades Reumáticas/tratamiento farmacológico , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/epidemiología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados/efectos adversos , Factores Biológicos/efectos adversos , Etanercept , Femenino , Humanos , Inmunoglobulina G/efectos adversos , Incidencia , Infliximab , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral , Sistema de Registros , Factores de Riesgo , EspañaRESUMEN
INTRODUCTION: Comparative data on synovial cell infiltrate and cytokine levels in anti citrullinated peptide/protein antibody (ACPA)-positive and ACPA negative rheumatoid arthritis (RA) patients are scarce. Our aim was to analyze synovial cell infiltrate and synovial fluid (SF) levels of cytokines in patients with RA according to the presence or absence of ACPA in serum. METHODS: A cross-sectional study in a single center including consecutive RA patients was performed. Patients were defined as 'ACPA negative' if serum was negative to two different ACPAs [second generation commercial anti-cyclic citrullinated peptide antibodies (CCP2) and chimeric fibrin/filaggrin citrullinated antibodies]. Parallel synovial tissue (ST) biopsies and SF were obtained by knee arthroscopy. Synovial cell infiltrate and endothelial cells were analyzed by immunohistochemistry and SF levels of Th1, Th2, Th17 and pro-inflammatory cytokines by Quantibody(R) Human Array. RESULTS: A total of 83 patients underwent arthroscopy, with a mean age of 55.9 ± 12 years, and mean disease duration of 45 months (interquartile range, IQR 10.8 to 122). 62% were female and 77% were ACPA positive. No significant differences were found in clinical variables, acute phase reactants, synovial cell infiltrate or lymphoid neogenesis (LN) between ACPA positive and negative patients. However ACPA positive patients had significantly higher levels of IL-1ß, IL-10, IL-17 F and CC chemokine ligand 20 (CCL-20) than ACPA negative patients. CONCLUSIONS: In our cohort of patients with RA no significant differences were found in synovial cell infiltrate or synovial LN according to ACPA status. However, ACPA positive patients had higher levels of T-cell derived and pro-inflammatory cytokines than ACPA negative patients. As systemic and local inflammation was similar in the two groups, these findings support a distinct synovial physiopathology.
Asunto(s)
Artritis Reumatoide/metabolismo , Citocinas/metabolismo , Líquido Sinovial/metabolismo , Membrana Sinovial/metabolismo , Artritis Reumatoide/inmunología , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Citrulina/inmunología , Estudios Transversales , Citocinas/análisis , Citocinas/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Proteínas Filagrina , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Líquido Sinovial/química , Membrana Sinovial/químicaRESUMEN
OBJECTIVE: To analyze longterm progression to rheumatoid arthritis (RA) and the predictive value of anticitrullinated peptide/protein antibodies (ACPA) in palindromic rheumatism (PR). METHODS: We selected all patients in our clinic with PR who had at least 1 ACPA measurement. We included only patients with pure PR, defined as no evidence of associated rheumatic disease at the first serum ACPA measurement. Clinical characteristics, serum ACPA levels, duration of PR until serum ACPA measurement, and total followup time were recorded. The outcome variable was the definitive diagnosis of RA. The prognostic value of ACPA status in pure PR for a definite diagnosis of RA was analyzed by different statistical methods. RESULTS: Seventy-one patients (54 women/17 men) with a PR diagnosis were included. Serum ACPA were positive in 52.1%. After a mean followup of 7.6 ± 4.7 years since the first ACPA measurement, 24 patients (33.8%) progressed to chronic disease: 22% RA, 5.6% systemic lupus erythematosus, and 5.6% other diseases. The positive likelihood ratio of ACPA status for RA was 1.45, and the area under the receiver-operating characteristic curve of ACPA titers was 0.60 (95% CI 0.45-0.75). Progression to RA was more frequently seen in ACPA-positive than in ACPA-negative patients (29.7% vs 14.7%), but the difference was not significant (hazard ratio 2.46, 95% CI 0.77-7.86). Mean ACPA levels of patients with pure PR did not differ significantly from those of patients who progressed to RA. CONCLUSION: ACPA are frequently found in the sera of patients with PR, and a significant proportion of these patients do not progress to RA in the long term.
Asunto(s)
Artritis Reumatoide/inmunología , Autoanticuerpos/inmunología , Péptidos Cíclicos/inmunología , Adulto , Anciano , Artritis Reumatoide/sangre , Autoanticuerpos/sangre , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Péptidos Cíclicos/sangre , PronósticoRESUMEN
INTRODUCTION: GBS is one of the most important causes of neonatal sepsis of vertical transmission (1-2% of the carriers). The infection may involve newborn's death or severe complications. The culture of vaginal and rectal GBS is a screening test and it is performed to all pregnant women between 35-37 weeks of gestation. If it is positive, intrapartum penicillin is prescribed. If it is negative or unknown, the antibiotic per protocol is given according to risk factors: rupture of membranes more than 18 hours, intrapartum temperature, or prematurity. The aim of this study is to quantify women who receive intrapartum antibiotic in relation to the positive culture and achievement with the SEGO's recommendation. MATERIAL AND METHODS: It describes a sample of 261 women of the Txagorritxu Hospital who have given birth during the work shift of researchers, excluding cesarean sections. VARIABLES: results of culture, antibiotic administration. Data were collected by reviewing and analyzed medical records using SPSS 17.0. RESULTS: From 261 women, 69 (26.4%) received antibiotic administration. From 69, 46 (66.67%) had a positive culture. 26 (37.68%) received antibiotics according to risk factors, although their cultures were negative or unknown. DISCUSSION: The results suggest there is a correct application of the SEGO's recommendation. Carrier women with no risk factors would not have received antibiotic therapy without screening.